# Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial

> **NCT06485544** · PHASE2 · RECRUITING · sponsor: **Tang-Du Hospital** · enrollment: 104 (estimated)

## Conditions studied

- Small Cell Lung Cancer (SCLC)

## Interventions

- **DRUG:** Adebrelimab + Etoposide + Platinum-based Therapy
- **DRUG:** Etoposide + Platinum-based Therapy

## Key facts

- **NCT ID:** NCT06485544
- **Lead sponsor:** Tang-Du Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2024-07-01
- **Primary completion:** 2025-12-30
- **Final completion:** 2026-12-30
- **Target enrollment:** 104 (ESTIMATED)
- **Last updated:** 2024-07-03


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06485544

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06485544, "Neoadjuvant Adebrelimab in Resectable SCLC: A Randomized Trial". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT06485544. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*